News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Sanofi-Aventis (France) Buys U.S. Cancer Firm, BiPar Sciences, Inc. for up to $500 Million
April 15, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- Sanofi-Aventis has agreed to buy private U.S. cancer specialist BiPar Sciences Inc. for up to $500 million in the latest bolt-on acquisition by the French drugmaker.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Mergers & acquisitions
Europe
Sanofi (France)
MORE ON THIS TOPIC
RNA editing
Lilly Makes $1.3B RNA Editing Bet With Rznomics to Build Out Hearing Loss Pipeline
May 16, 2025
·
2 min read
·
Tristan Manalac
C-suite
UPDATED: With Novo CEO’s Sudden Exit, Analysts Worry ‘There’s Something Pretty Wrong Here’
May 16, 2025
·
5 min read
·
Annalee Armstrong
Deals
Bluebird’s Private Equity Buyout Boosts Upfront Cash for Shareholders
May 15, 2025
·
1 min read
Manufacturing
Sanofi Hops Aboard US Manufacturing Blitz With $20B Commitment
May 15, 2025
·
2 min read
·
Tristan Manalac
